Libtayo® Received FDA Aproval As First And Only Treatment For Second Most Common Skin Cancer
Libtayo® Received FDA Aproval As First And Only Treatment For Second Most Common Skin Cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery [..]